Active Pharmaceutical Ingredients CDMO Market Size, Share & Trends Analysis Report By Product (Highly Potent API, Antibody Drug Conjugate), By Synthesis, By Drugs, By Application, By Workflow- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2021-2027

The global Active Pharmaceutical Ingredients CDMO market gathered revenue around USD 81.9 Billion in 2020 and market is set to grow USD 135.7 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 6.0% during the prediction period 2021 to 2027.

Growth Factors:

The market Increasing pharmaceutical R&D investment, patent expirations, and rise in demand for generic drugs and biologic innovation are the factors driving the market.

The growth of small molecules, rising Active Pharmaceutical Ingredient (API) complexity, and the need to reduce costs are factors contributing to the rapid expansion of outsourcing services in the pharmaceutical sector. Only a few companies have achieved global reach and scale in the Contract Development and Manufacturing Organization (CDMO) sector, which is still fragmented. Besides, many companies are providing one-stop-shop solutions as an integrated source of APIs and formulations.

However, due to the COVID-19 pandemic, governments worldwide have opted to boycott APIs made in China. Due to government-imposed lockdown limitations in China, 44 firms were declared non-operational during the pandemic. As a consequence, various countries have launched programs to develop their own APIs, and countries across the EU have re-evaluated their healthcare models in order to combat the virus and ensure a steady supply of APIs.

COVID-19 has placed unprecedented expectations on API makers, as evidenced by the substantial increase in demand for medications required to manage critically ill patients on mechanical ventilation. As a result, the sudden need to rapidly increase production has emphasized the need for adaptability for API CDMOs in maintaining drug supply, with some companies proving better able to withstand the pressures of quick scale up than others.

This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Active Pharmaceutical Ingredients CDMO market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Active Pharmaceutical Ingredients CDMO market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.

Report Coverage

Report Scope Details
Market Size USD 135.7 Billion  by 2027
Growth Rate CAGR of 6.0% From 2021 to 2027
Base Year 2020
Forecast Period 2021 to 2027
Historic Data 2017 to 2020
Report coverage Growth Factors, Revenue Status, Competitive Landscape,  and Future Trends
Segments Covered Product, synthesis, drug, application, workflow And Region
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)
Companies Mentioned  Cambrex; Recipharm; Thermo Fisher Pantheon; Corden Pharma; Samsung Biologics; Lonza; Catalent; Siegfried; Piramal Pharma Solutions; Boehringer Ingelheim.

COVID-19 Impact Assessment on Market Landscape

The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.

Active Pharmaceutical Ingredients CDMO market Report empowers readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.

Regional analysis:

Asia Pacific dominated the active pharmaceutical ingredients CDMO market and accounted for the largest revenue share of 46.9% in 2020. The segment is anticipated to register the fastest CAGR of 8.12% throughout the forecast period. The significantly cheaper manufacturing costs as compared to North America and Europe and favorable laws in the region particularly China and India are factors dominating the market for active pharmaceutical ingredients CDMO in the region. While China and India have established themselves as important providers of active pharmaceutical ingredient manufacturing services, the U.S. continues to be the principal outsourcing hub for pharmaceutical development. This is due to a combination of enormous amounts of financing and a unique concentration of university-affiliated pharmaceutical research hubs.

The increased importance of conventional medications and the rapidly increasing occurrence of persistent infections are important factors for the Indian API market to grow favorably. Generic APIs are exported from India to developed countries, accounting for 41.8% of total sales in India versus 24.9% in China. According to the Chemical Pharmaceutical Generic Association Research, India is the second-largest provider of generic active pharmaceutical ingredients to the U.S. market, with a 24.6% share. The country is also boosting its supply to Western Europe, which accounts for 19.3% of the region's total supply. According to recent findings, China accounts for 31% of the global nonexclusive API vendor market. Following China, the U.S. and India are the leading producers of nonexclusive APIs. As a result, India has become a major outsourcing center manufacturing active pharmaceutical ingredients.

Competitive Rivalry

Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

  • Company Overview
  • Company Market Share/Positioning Analysis
  • Product Offerings
  • Financial Performance
  • Recent Initiatives
  • Key Strategies Adopted by Players
  • Vendor Landscape
  • List of Suppliers
  • List of Buyers

Some of the prominent players in the Active Pharmaceutical Ingredients CDMO Market include:  Cambrex; Recipharm; Thermo Fisher Pantheon; Corden Pharma; Samsung Biologics; Lonza; Catalent; Siegfried; Piramal Pharma Solutions; Boehringer Ingelheim.

Unravelling the Critical Segments

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:

  • By Product
    • Traditional Active Pharmaceutical Ingredient (Traditional API)
    • Highly Potent Active Pharmaceutical Ingredient (HP-API)
    • Antibody Drug Conjugate (ADC)
    • Others
  • By Synthesis
    • Synthetic
    • Biotech
  • By Drug
    • Innovative
    • Generics
  • By Workflow
    • Clinical
    • Commercial
  • By Application
    • Oncology
    • Hormonal
    • Glaucoma
    • Cardiovascular
    • Diabetes
    • Others

By Geography

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Highlights of the Report:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the market.
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market
  • Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the market

Research Methodology

In the study, a unique research methodology is utilized to conduct extensive research on the growth of the Active Pharmaceutical Ingredients CDMO market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the Active Pharmaceutical Ingredients CDMO market study are as follows - statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the market, and makes the projections on the growth prospects of the Active Pharmaceutical Ingredients CDMO markets more accurate and reliable.

Secondary Research

It involves company databases such as Hoover's: This assists us recognize financial information, structure of the market participants and industry competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire based research etc.
  • In order to validate our research findings and analysis we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

Industry participants involved in this research study include:

  • CEOs, VPs, market intelligence managers
  • Procuring and national sales managers technical personnel, distributors and resellers
  • Research analysts and key opinion leaders from various domains

Key Points Covered in Active Pharmaceutical Ingredients CDMO market Study:

  • Growth of Active Pharmaceutical Ingredients CDMO in 2021
  • Market Estimates and Forecasts (2017-2027)
  •  Brand Share and Market Share Analysis
  •  Key Drivers and Restraints Shaping Market Growth
  •  Segment-wise, Country-wise, and Region-wise Analysis
  •  Competition Mapping and Benchmarking
  •  Recommendation on Key Winning Strategies
  •  COVID-19 Impact on Demand for Active Pharmaceutical Ingredients CDMO and How to Navigate
  •  Key Product Innovations and Regulatory Climate
  •  Active Pharmaceutical Ingredients CDMO Consumption Analysis
  •  Active Pharmaceutical Ingredients CDMO Production Analysis
  •  Active Pharmaceutical Ingredients CDMO and Management